Clinical Trials Browser

Interventional × Adenocarcinoma of Lung × pembrolizumab × Clear all

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

214 enrolled

Thoracic

Adenocarcinoma of Lung

NCT05887492 2025-11-18

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Phase 1/2 Recruiting

126 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT04533451 2025-06-13

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Phase 2 Active not recruiting

101 enrolled 21 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05266846 2024-05-30

BEYOND

Phase 2 Recruiting

78 enrolled

Thoracic

Adenocarcinoma of Lung

NCT04027946 2024-04-16

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

6 enrolled 14 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04682431 2024-03-22

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1 Terminated

127 enrolled

BreastGastrointestinalHead & NeckThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04691375 2024-03-22

A Study of PY314 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

86 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

154 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04452214 2023-07-14

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Phase 1 Completed

19 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma

NCT03254004 2020-12-14

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Phase 2 Unknown

70 enrolled

Thoracic

Adenocarcinoma of Lung

Clinical Trials

CheckCell-2

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

CRYOMUNE

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

BEYOND

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Study of PY314 in Subjects With Advanced Solid Tumors

BLISS

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm